GÖTEBORG, 15 april 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Tuesday, May 19, 2026.
The information in the press release is intended for investors.
The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the annual general meeting held on Tuesday, May 19, 2026 at 3 p.m. at Biotech Center, Arvid Wallgrens backe 20, Fl. 5, Gothenburg, Sweden. Registration at the annual general meeting starts at 2:30 p.m. and ends when the meeting convenes.
The complete notice to attend is available in Swedish on the company´s website, www.isofolmedical.com
For more information, please contact
Isofol Medical AB (publ)
Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0)738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CEST on April 15, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.
www.isofolmedical.com